N-methyl-N-(4-1H-imidazol-4-ylphenyl)amine | 89250-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-methyl-N-(4-1H-imidazol-4-ylphenyl)amine
• 英文别名: 4-(1H-imidazol-5-yl)-N-methylaniline
• CAS: 89250-14-6
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: PBRXATIPHRYUEW-UHFFFAOYSA-N

物化性质

• 沸点：
  437.9±28.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-N-(4-1H-imidazol-4-ylphenyl)amine 以 乙醇 、 水 为溶剂， 生成 N-isopropyl-N'-methyl-N'-(4-1H-imidazol-4-ylphenyl)formamidine
  参考文献：
  名称：

  Bazzano; Vavoni; Mondoni, European Journal of Medicinal Chemistry, 1986, vol. 21, # 1, p. 27 - 33

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(1H-咪唑-4-基)苯胺盐酸盐 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 N-methyl-N-(4-1H-imidazol-4-ylphenyl)amine
  参考文献：
  名称：

  Bazzano; Vavoni; Mondoni, European Journal of Medicinal Chemistry, 1986, vol. 21, # 1, p. 27 - 33

  摘要：

  DOI：

文献信息

• Formamidine derivatives and pharmaceutical use
  申请人：Istituto de Angeli S.p.A.

  公开号：US04666932A1

  公开（公告）日：1987-05-19

  Compounds of the formula ##STR1## wherein R is hydrogen or methyl; R.sub.1 is straight or branched alkyl of 1 to 6 carbon atoms, dimethyldioxolylmethyl, hydroxymethyldioxolylmethyl, hydroxy(alkyl of 1 to 6 carbon atoms), mono- or di-(alkoxy of 1 to 6 carbon atoms)(alkyl of 1 to 6 carbon atoms), (alkyl of 1 to 6 carbon atoms)thio- (alkyl of 1 to 6 carbon atoms), (alkoxy of 1 to 6 carbon atoms)(alkyl of 1 to 6 carbon atoms)thio-(alkyl of 1 to 6 carbon atoms), cyano(alkyl of 1 to 6 carbon atoms), di-lower alkyl-amino(alkyl of 1 to 6 carbon atoms), alkenyl, alkynyl, or cycloalkyl; R.sub.2 and R.sub.3 are each independently hydrogen, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms or halogen; and Z is imidazol-2-yl or imidazol-4-yl; provided however that, when R.sub.1 is straight or branched alkyl, alkenyl, alkynyl, cycloalkyl or cyano and R, R.sub.2 and R.sub.3 are hydrogen, Z is other than imidazol-4-yl; tautomers thereof and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antiulcerogenics and gastric acid secretion inhibitors.

  公式为 ##STR1## 的化合物，其中R为氢或甲基；R.sub.1为1-6个碳原子的直链或支链烷基，二甲基二氧杂环己基甲基，羟甲基二氧杂环己基甲基，羟基(1-6个碳原子的烷基)，单-或双-(1-6个碳原子的烷氧基)(1-6个碳原子的烷基)，(1-6个碳原子的烷基)硫-(1-6个碳原子的烷基)，(1-6个碳原子的烷氧基)(1-6个碳原子的烷基)硫-(1-6个碳原子的烷基)，氰基(1-6个碳原子的烷基)，双-低烷基-氨基(1-6个碳原子的烷基)，烯基，炔基或环烷基；R.sub.2和R.sub.3各自独立地为氢，1-3个碳原子的烷基，1-3个碳原子的烷氧基或卤素；Z为咪唑-2-基或咪唑-4-基；但是，当R.sub.1为直链或支链烷基，烯基，炔基，环烷基或氰基，且R，R.sub.2和R.sub.3为氢时，Z不是咪唑-4-基；它们的互变异构体和非毒性、药理学上可接受的酸盐也是有用的抗溃疡和胃酸分泌抑制剂。
• Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use
  申请人：ISTITUTO DE ANGELI S.p.A.

  公开号：EP0094727A2

  公开（公告）日：1983-11-23

  Object of the present invention are new pharmacologically active substituted heterocyclylphenylformamidines of formula in which A represents a hydrogen atom, an amino group which may be substituted by one or two alkyl groups having 1 to 3 carbon atoms or a saturated heterocyclic ring, R represents a hydrogen atom or a methyl group, R1 represents a linear or branched alkyl group which may contain 1 or 2 heteroatoms such as a sulfur, an oxygen or nitrogen atom or may form a substituted or an unsubstituted cyclic ring, an alkenyl group, an alkynyl group, a cycloalkyl group or a phenyl group, R2 and R3 which may be the same or different, represent a hydrogen atom, an alkyl or alkoxy group having 1 to 3 carbon atom or a halogen atom, m and n represent 0 or 1, Het represents a substituted or unsubstituted heterocyclic ring containing from 1 to 3 heteroatoms (except the imidazole ring when R1 is a linear or branched alkyl group not containing heteroatoms and R2 and R3 are both hydrogen atoms), tautomers thereof and acid addition salts of the aforesaid compounds. Processes for preparation of the compounds of formula (I) and their intermediates as well as pharmaceutical compositions containing them are also object of this invention. The new compounds are H2-receptor blocking agents, inhibit gastric acid secretion, and are useful antiulcer agents.

  本发明的目的是具有药理活性的新的取代杂环苯基甲脒，其式为 其中 A 代表氢原子、可被一个或两个具有 1 至 3 个碳原子的烷基或饱和杂环取代的氨基，R 代表氢原子或甲基，R1 代表直链或支链烷基，该烷基可含有 1 或 2 个杂原子，如硫原子、氧原子或氮原子，或可形成取代或未取代的环环、烯基、炔基、环烷基或苯基、R2和R3可以相同或不同，代表氢原子、具有1至3个碳原子的烷基或烷氧基或卤素原子，m和n代表0或1，Het代表含有1至3个杂原子的取代或未取代的杂环（当R1为不含杂原子的直链或支链烷基且R2和R3均为氢原子时，咪唑环除外）、其同系物以及上述化合物的酸加成盐。制备式（I）化合物及其中间体以及含有它们的药物组合物的工艺也是本发明的目的。 新化合物是 H2 受体阻断剂，可抑制胃酸分泌，是有效的抗溃疡剂。
• SILICON-CONTAINING COMPOUND FOR RESISTANCE TO HEPATITIS C VIRUS INFECTION
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3604295A1

  公开（公告）日：2020-02-05

  The present invention provides a silicon-containing compound for resistance to hepatitis c virus infection, and in particular provides a compound represented by formula I, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, a preparation process therefor, and a pharmaceutical composition comprising the same. The present application also provides a use of the compound, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, and a pharmaceutical composition comprising the same in treatment of hepatitis c virus infection.

  本发明提供了一种用于抵抗丙型肝炎病毒感染的含硅化合物，特别是提供了一种由式I代表的化合物，或其药学上可接受的盐，或其同系物，或其立体异构体，或其氘代化合物，以及它们之间的混合物，其制备工艺，以及由其组成的药物组合物。本申请还提供了该化合物或其药学上可接受的盐、或其同分异构体、或其立体异构体、或其氘代化合物及其混合物以及包含其的药物组合物在治疗丙型肝炎病毒感染中的用途。